Bristol-Myers' Opdivo extends survival in head and neck cancer -study

April 19 (Reuters) - Bristol-Myers Squibb's cancer immunotherapy drug, Opdivo, helped advanced head and neck cancer patients with a dismal prognosis live longer than other standard treatments, according to data from a late-stage study presented on Tuesday.